Positive Results for TYSABRI
Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab)…
Part of the
network
network
Tag: Phase III
Axonyx Shares Suffer Due to Drug Failure
Axonyx shares went down after the company said a clinical trial of a drug failed to achieve its goals.
